SCHEMBL30061390

SCHEMBL30061390

O=C(C1CCCN(C(=O)C2CCCCC2)C1)N1CCN(c2cc(C(F)(F)F)nc3ccccc23)CC1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.57
MAPK1 P28482 2/20 0.53
ADRB2 P07550 1/20 0.52
DRD2 P14416 2/20 0.49
DRD3 P35462 2/20 0.49
DPP4 P27487 1/20 0.49
DPP8 Q6V1X1 1/20 0.49
DPP9 Q86TI2 1/20 0.49
HCRTR1 O43613 1/20 0.48
HCRTR2 O43614 1/20 0.48
TSHR P16473 2/20 0.47
IDE P14735 1/20 0.46
POLB P06746 1/20 0.44
KDM4E B2RXH2 1/20 0.44
NCF1 P14598 1/20 0.43
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
CNR1 P21554 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31078086 0.89 MAPT (0.52) MAPTMAPK1ADRB2DRD2DRD3
SCHEMBL23363311 0.89 MAPT (0.52) MAPTMAPK1ADRB2DRD2DRD3
SCHEMBL23363214 0.89 MAPT (0.52) MAPTMAPK1ADRB2DRD2DRD3
SCHEMBL23363215 0.89 MAPT (0.52) MAPTMAPK1ADRB2DRD2DRD3
SCHEMBL30059034 0.89 MAPT (0.59) MAPTMAPK1ADRB2DRD2DRD3
SCHEMBL30058789 0.89 MAPT (0.58) MAPTMAPK1ADRB2DRD2DRD3
SCHEMBL23362042 0.86 LMNA (0.61) MAPTMAPK1POLBKDM4EMEN1
SCHEMBL31733963 0.86 LMNA (0.61) MAPTMAPK1POLBKDM4EMEN1
SCHEMBL30058781 0.86 POLB (0.64) MAPTMAPK1ADRB2POLBNPSR1
SCHEMBL30060832 0.85 NCF1 (0.62) MAPTMAPK1ADRB2HCRTR1HCRTR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12612384-B2 Heterocyclic CYP4A inhibitor compounds and compositions thereof MBD Co., Ltd. (KR) 2026-04-28 US claimed
US-20240287032-A1 NOVEL HETEROCYCLIC COMPOUND AND USE THEREOF MBD Co., Ltd. (KR) 2024-08-29 US claimed
US-12612384-B2 Heterocyclic CYP4A inhibitor compounds and compositions thereof MBD Co., Ltd. (KR) 2026-04-28 US disclosed
US-20240287032-A1 NOVEL HETEROCYCLIC COMPOUND AND USE THEREOF MBD Co., Ltd. (KR) 2024-08-29 US disclosed
WO-2022235091-A1 NOVEL HETEROCYCLIC COMPOUND AND USE THEREOF 엠비디 주식회사 2022-11-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240287032-A1 NOVEL HETEROCYCLIC COMPOUND AND USE THEREOF CYP4B1, CYP4A11, CYP3A4 MAPT 3959/4885MAPK1 1954/4885ADRB2 916/4885
US-12612384-B2 Heterocyclic CYP4A inhibitor compounds and compositions thereof CYP4A11, CYP4B1, CYP4A22 MAPT 2797/4885MAPK1 1958/4885ADRB2 288/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.